Benign prostatic hyperplasia (BPH) management in the primary care setting

Canadian Journal of Urology

Volumn 19, Issue , 2012, Pages 10-17

  Kapoor, Anil ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

5 alpha reductase inhibitors; Alpha blockers; Benign prostatic hyperplasia (BPH); Combination therapy; Pharmacotherapy; Phosphodiesterase 5 inhibitors

Indexed keywords

ARTICLE; HUMAN; MALE; PRIMARY HEALTH CARE; PROSTATE HYPERTROPHY;

HUMANS; MALE; PRIMARY HEALTH CARE; PROSTATIC HYPERPLASIA;

EID: 84876451214     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. McConnell JD, Bruskewitz R, Walsh P et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Effi cacy and Safety Study Group. N Engl J Med 1998;338(9):557-563.
2. Roehborn CG. Benign prostatic hyperplasia: an overview. Rev Urol 2005;7(9):S3-S14.
3. Barry MJ, Fowler FJ, O'Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148(5):1549-1557; discussion 1564.
4. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006;296(19):2319-2328.
5. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999;5(3)3: 581-589.
6. Boyle P, Robertson C, Lowe F, Roehrborn C. Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000;55(4):533-539.
7. Bent S, Kane C, Shinohara K et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006;354(6):557-566.
8. MacDonald R, Wilt TJ, Howe RW. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. BJU Int 2004;94(9):1263-1270.
9. MacDonald R, Wilt TJ. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: A systematic review of efficacy and adverse effects. Urology 2005; 66(4):780-788.
10. Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alphaadrenoceptor antagonists. BJU Int 2005;95(Suppl 4):29-36.
11. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of a1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36(1):1-13.
12. Kaplan S, McConnell J, Roehrborn C et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 mL or greater. J Urol 2006;175(1):217-220; discussion 220-221.
13. Kazuki K, Masaki Y, Yukio H for the Silodosin Clinical Study Group. Silodosin, a new alpha 1a-adrenoceptor selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 2006;98(5):1019-1024.
14. Montorsi F. Profile of silodosin. Eur Urol 2010;9(Suppl):491-495. Corrigendum. Eur Urol 2011;59(2):315.
15. Morganroth J, Lepor H, Hill LA, Volinn W, Hoel G. Effects of the selective a1A-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double blind, placebomoxifloxacin-controlled study. Clin Pharmacol Ther 2010;87(5): 609-613.
16. Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernandez E: European Silodosin Study Group. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo-and active-controlled clinical trial performed in Europe. Eur Urol 2011;59(3): 342-352.
17. Yu HJ, Lin AT, Yang SS et al. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). BJU Int 2011;108(11):1843-1848.
18. Miyakita H, Yokoyama E, Onodera Y et al. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia. Int J Urol 2010;17(10): 869-875.
19. Yukio H, Kazuki K, Masayuki T, Masaki Y. Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia. Urology 2010;76(6):1446-1450.
20. Nickel JC, O'Leary MP, Lepor H et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double-blind, placebo controlled study. J Urol 2011;186(1):125-131.
21. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G; ARIA3001 ARIA 3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60(3):434-441.
22. Steers WD. 5 alpha-reductase activity in the prostate. Urology 2001;58(6 Suppl 1):17-24:discussion 24.
23. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Eur Urol 2000;37(4):367-380.
24. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alphareductase inhibitor. J Clin Endocrinol Metab 2004;89(5):2179-2184.
25. Gormley GJ, Stoner E, Bruskewitz RC et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992;327(17):1185-1191.
26. Health Canada. Finasteride (Proscar, Propecia) and dutasteride (Avodart, Jalyn): may increase the risk of high grade prostate cancer. 2012 March: http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2012/2012_38-eng.php.
27. Roehrborn CG, Nickel JC, Andriole GL et al. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. Urology 2011:78(3):641-646.
28. McConnell JD, Roehrborn CG, Bautista OM et al; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003:349(25):2387-2398.
29. Roehrborn CG, Siami P, Barkin J et al; CombATStudyGroup. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. Eur Urol 2009;55(2):461-471.
30. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinacional Surrey of the aging male (MSAM-7). Eur Urol 2003;44(6):637-649.
31. McVary KT, McKenna KE. The relationship between erectile dysfunction and lower urinary tract symptoms: Epidemiological, clinical, and basic science evidence. Curr Urol Rep 2004;5(4):251-257.
32. Gacci M, Eardley I, Giuliano F et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011;60(4):809-825.
33. Andersson KE, de Groat WC, McVary KT et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn 2011;30(3):292-301.
34. McVary KT, Roehrborn CG, Kaminetsky JC et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177(4):1401-1407.
35. McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, Van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007;177(3):1071-1077.
36. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomized, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008;53(6): 1236-1244.
37. Tamimi NA, Mincik I, Haughie S. A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. BJU Int 2010;106(5):674-680.
38. Egerdie RB, Auerbach S, Roehrborn CG et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in med with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med 2011;9(1):271-281.
39. Nickel JC, Méndez-Probst CE, Whelan TF, Paterson RF, Razvi H. 2010 Update: Guidelines for the management of benign prostatic hyperplasia. Can Urol Assoc J 2010;4(5):310-316.